Black Rock Inc. Protara Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 115,273 shares of TARA stock, worth $621,321. This represents 0.0% of its overall portfolio holdings.

Number of Shares

115,273

Previous 30,864 273.49%

Holding current value

$621,321

Previous $123,000 94.31%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.96 - $4.14 $165,441 - $349,453	84,409 Added 273.49%	115,273 $239,000
Q1 2024 May 10, 2024	SELL	$1.86 - $4.83 $6,420 - $16,673	-3,452 Reduced 10.06%	30,864 $123,000
Q4 2023 Feb 13, 2024	SELL	$1.12 - $1.93 $320 - $551	-286 Reduced 0.83%	34,316 $64,000
Q3 2023 Nov 13, 2023	SELL	$1.64 - $2.93 $2,683 - $4,793	-1,636 Reduced 4.51%	34,602 $57,000
Q2 2023 Aug 11, 2023	SELL	$2.27 - $3.59 $1,938 - $3,065	-854 Reduced 2.3%	36,238 $86,000
Q1 2023 May 12, 2023	BUY	$2.76 - $3.91 $2,020 - $2,862	732 Added 2.01%	37,092 $116,000
Q4 2022 Feb 13, 2023	BUY	$2.43 - $3.7 $2,087 - $3,178	859 Added 2.42%	36,360 $97,000
Q3 2022 Nov 14, 2022	SELL	$2.96 - $4.27 $8,900 - $12,839	-3,007 Reduced 7.81%	35,501 $105,000
Q2 2022 Aug 12, 2022	SELL	$2.8 - $5.33 $1,142 - $2,174	-408 Reduced 1.05%	38,508 $113,000
Q1 2022 May 12, 2022	SELL	$4.19 - $6.9 $5,128 - $8,445	-1,224 Reduced 3.05%	38,916 $200,000
Q4 2021 Feb 10, 2022	SELL	$6.15 - $7.76 $23,960 - $30,232	-3,896 Reduced 8.85%	40,140 $271,000
Q3 2021 Nov 09, 2021	BUY	$6.38 - $9.3 $24,952 - $36,372	3,911 Added 9.75%	44,036 $306,000
Q2 2021 Aug 11, 2021	BUY	$8.68 - $16.99 $348,285 - $681,723	40,125 New	40,125 $391,000

Others Institutions Holding TARA

# of Institutions

Shares Held

10.7M

Call Options Held

Put Options Held

1.8K

View Full List

About Protara Therapeutics, Inc.

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $60.7M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

More about TARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account